Can the combination of ALSFRS and survival time analysis impact the outcome in phase IIIALS clinical trials?

Muscle & NerveVolume 47, Issue 5 p. 779-779 Letter to the Editor Can the combination of ALSFRS and survival time analysis impact the outcome in phase III ALS clinical trials? Raghav Govindarajan MD, Raghav Govindarajan MD Department of Neurology, Cleveland Clinic Florida, Weston, FloridaSearch for more papers by this author Raghav Govindarajan MD, Raghav Govindarajan MD Department of Neurology, Cleveland Clinic Florida, Weston, FloridaSearch for more papers by this author First published: 18 November 2012 https://doi.org/10.1002/mus.23728Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Healy BC, Schoenfeld D. Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis. Muscle Nerve 2012; 46: 506– 511. 2Wang M, Cairncross G, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402. Int J Radiat Oncol Biol Phys 2010; 77: 662– 669. 3Brettschneider J, vanDeerlin VM, Robinson JL, Kwong L, Lee EB, Ali YO, et al. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol 2012; 123: 825– 839. 4Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002; 25: 709– 714. 5Nelson ND, Trail M, Van JN, Appel SH, Lai EC. Quality of life in patients with amyotrophic lateral sclerosis: perceptions, coping resources, and illness characteristics. J Palliat Med 2003; 6: 417– 424. 6Rusina R, Ridzon P, Kulist'ák P, Keller O, Bartos A, Buncovaá M, et al. Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study. Eur J Neurol 2010; 17: 23– 30. 7Rutkove S. Electrical impedance myography as a biomarker for ALS. Lancet Neurol 2009; 8: 226. Volume47, Issue5May 2013Pages 779-779 ReferencesRelatedInformation